2022
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Johnson B, Haymaker C, Parra E, Soto L, Wang X, Thomas J, Dasari A, Morris V, Raghav K, Vilar E, Kee B, Eng C, Parseghian C, Wolff R, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba I, Futreal A, Kopetz S, Overman M. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Journal For ImmunoTherapy Of Cancer 2022, 10: e005332. PMID: 36007963, PMCID: PMC9422817, DOI: 10.1136/jitc-2022-005332.Peer-Reviewed Original ResearchConceptsMicrosatellite stable (MSS) metastatic colorectal cancerTreatment-related adverse eventsMetastatic colorectal cancerResponse rateStable diseasePartial responsePD-1Lung metastasesColorectal cancerT cellsCommon treatment-related adverse eventsMedian age 48 yearsMedian progression-free survivalTumor microenvironmentCombination of trametinibPhase II studyPhase II trialProgression-free survivalCD8 T cellsImmune checkpoint blockadeT cell infiltrationImmune tumor microenvironmentOverall response rateAge 48 yearsComparison of baseline
2019
Association of TGF-β expression with intratumoral infiltration of cytotoxic T lymphocytes in patients with microsatellite-stable colorectal cancer.
Mehrvarz Sarshekeh A, Katkhuda R, Verma A, Advani S, Overman M, Maru D, Kopetz S. Association of TGF-β expression with intratumoral infiltration of cytotoxic T lymphocytes in patients with microsatellite-stable colorectal cancer. Journal Of Clinical Oncology 2019, 37: 3577-3577. DOI: 10.1200/jco.2019.37.15_suppl.3577.Peer-Reviewed Original ResearchConsensus molecular subtype 4Colorectal cancerMSS colorectal cancerEMT gene signatureCTL infiltrationIntratumoral infiltrationImmune cellsTumor microenvironmentGene signatureMicrosatellite stable colorectal cancerAssociation of TGFInfiltration of CTLsHigh relapse rateRank correlation analysisCytotoxic T lymphocytesTGF-β expressionTGF-β activationExpression levelsTGF-β pathwayParaffin-embedded samplesRelapse rateImmunotherapy responseMacrophage infiltrationPoor prognosisTumor infiltration